Overactive Bladder and Urgency Urinary Incontinence

Overactive bladder is a clinical syndrome of urinary urgency (a sudden, compelling desire to void that is difficult to defer). It is typically accompanied by increased daytime urinary frequency and nocturia. Urgency urinary incontinence (involuntary leakage immediately preceded by or associated with urgency) may or may not be present.

It reflects involuntary detrusor muscle contraction during the bladder filling phase, in the absence of an identifiable local pathological cause such as infection or bladder stone. It is extremely common and affects both men and women.

The underlying mechanism and required treatment are fundamentally different from stress incontinence. Accurate clinical distinction matters, because the two frequently coexist as mixed incontinence in a substantial proportion of affected individuals.

Pathophysiology

• The underlying pathophysiology is detrusor overactivity: involuntary detrusor muscle contraction during the bladder filling and storage phase, rather than being restricted to the voluntary voiding phase.
• The mechanism is incompletely understood in most idiopathic cases. It is believed to involve altered afferent bladder sensory signalling, altered central nervous system processing and inhibitory control of bladder function, and, in some cases, subtle, localised changes within the detrusor muscle affecting its contractile regulation.
• Neurogenic detrusor overactivity occurs with neurological conditions (including multiple sclerosis, spinal cord injury, and stroke) that disrupt the central nervous system pathways regulating bladder storage and voiding. It is a distinct category with additional management considerations relevant to the underlying neurological context.
• Bladder outlet obstruction (particularly in men with benign prostatic hyperplasia) can produce secondary detrusor overactivity. This reflects compensatory detrusor muscle changes in response to chronic outflow resistance. Identify and address this contributing factor when assessing overactive bladder symptoms in men.

• Urinary urgency, a sudden, compelling desire to void that is difficult to defer, is the core, defining symptom.
• It is typically accompanied by increased daytime urinary frequency (generally defined as voiding eight or more times over a twenty four hour period) and nocturia (waking one or more times overnight specifically to void).
• Urgency urinary incontinence is involuntary leakage in association with urgency, in contrast to the physical exertion trigger of stress incontinence. It occurs in a substantial proportion, though not all, of affected individuals.
• The characteristic pattern involves little or no warning before the urge to void becomes overwhelming. Patients frequently describe a need to rush to the toilet and, in a proportion, leakage before they reach it in time.
• This is a distressing and functionally limiting pattern with considerable impact on daily activities and social engagement, including confidence to travel or engage in activities away from readily accessible toilet facilities.
• A structured bladder diary, as detailed under urinary incontinence generally, objectively characterises the pattern, frequency and severity of urgency and leakage episodes. It supports diagnosis and monitoring of treatment response.
• Explore associated symptoms or history suggesting an alternative or contributing cause: recurrent urinary tract infection, haematuria, or relevant neurological symptoms or a known neurological diagnosis.
• Haematuria raises concern for bladder malignancy or stone disease and warrants specific further investigation. Where an underlying or contributing cause is identified, it needs its own management.

• The essential initial approach follows the general principles detailed under urinary incontinence. It comprises full clinical history and examination and a structured bladder diary.
• Urinalysis excludes urinary tract infection and identifies haematuria warranting further investigation.
• Post-void residual bladder volume excludes significant coexisting overflow incontinence or bladder outlet obstruction.
• Overactive bladder is generally diagnosed clinically from the characteristic symptom pattern once these alternative or contributing causes have been reasonably excluded.
• Cystoscopy and further bladder imaging are reserved for cases with red flag features (particularly haematuria) or diagnostic uncertainty, to exclude bladder malignancy or other structural pathology. They are not routinely required for the typical diagnosis of overactive bladder itself.
• Urodynamic studies directly and objectively demonstrate detrusor overactivity during bladder filling. They are generally reserved for diagnostic uncertainty, significant mixed incontinence symptoms requiring clarification of the predominant mechanism, or inadequate response to initial, standard treatment. Similar principles apply as detailed under stress incontinence.

• Behavioural and lifestyle interventions are first line management. Bladder training is a structured programme of progressively increasing the interval between voids, aiming to gradually increase functional bladder capacity and reduce urgency frequency over time.
• Fluid management advice: avoid excessive fluid intake while ensuring adequate hydration, and specifically reduce caffeine and alcohol intake, given their bladder irritant and diuretic properties respectively.
• Weight loss where body mass index is elevated.
• Pelvic floor muscle training, classically associated with stress incontinence, also gives some benefit for urgency symptoms through enhanced ability to voluntarily suppress an involuntary detrusor contraction.
• Antimuscarinic (anticholinergic) medications, including oxybutynin, tolterodine, and solifenacin, are standard first line pharmacological treatment where behavioural interventions alone give inadequate symptom control. They reduce detrusor overactivity through blockade of muscarinic receptors.
• Consider the anticholinergic adverse effect profile carefully: dry mouth, constipation and, of particular and increasing concern in older adults, cognitive impairment. Accumulating evidence supports an association between cumulative anticholinergic medication burden and increased dementia risk in this population.
• This favours cautious use and consideration of alternative approaches, particularly in older or cognitively vulnerable patients.
• Mirabegron and vibegron are beta-3 adrenergic receptor agonists. They work through an alternative mechanism (detrusor muscle relaxation during bladder filling via a different receptor pathway) without the anticholinergic adverse effect profile.
• They are an increasingly preferred alternative or adjunctive option, particularly for older adults or others where anticholinergic burden is a concern. Mirabegron requires some caution and blood pressure monitoring, given a recognised potential for modest blood pressure elevation.
• Botulinum toxin injection into the detrusor muscle is delivered via cystoscopic injection under local or general anaesthesia. It is effective for overactive bladder not adequately responding to an adequate trial of behavioural and pharmacological treatment.
• The effect typically lasts several months before repeat injection is needed. There is an important risk of urinary retention requiring intermittent self-catheterisation in a proportion of treated patients, which is essential to counsel on before proceeding.
• Sacral neuromodulation (surgical implantation of a device providing targeted electrical stimulation to the sacral nerve roots regulating bladder function) and, less commonly, percutaneous tibial nerve stimulation are further advanced options for refractory overactive bladder. They are generally delivered through specialist urology or urogynaecology services.
• Treat and address any identified underlying or contributing cause as an integral part of individualised management. Examples are bladder outlet obstruction in men, and the specific considerations for neurogenic detrusor overactivity with an underlying neurological condition.
• Regular, structured follow up assesses treatment response, tolerability and ongoing symptom burden. Escalate stepwise through the treatment options according to individual response. This condition is common, frequently treatable, and often significantly impairs quality of life.